Advances in the Molecular Pathophysiology and Emerging Therapeutic Strategies for Diabetic Retinopathy
Authors:
- Lidianys María Lewis-LujánLLLidianys María Lewis-Luján
- Diego Emmanuel Guerrero-MagañaDGDiego Emmanuel Guerrero-Magaña
- Annette Pulcherie Iloki-LewisAIAnnette Pulcherie Iloki-Lewis
- Juan Carlos Gálvez RuízJRJuan Carlos Gálvez Ruíz
- Mikhail Alekseevich OsadchukMOMikhail Alekseevich Osadchuk
- Arsenii Alekseevich RascheskovARArsenii Alekseevich Rascheskov
- Maxim Victorovich TrushinMTMaxim Victorovich Trushin
- Judas Vargas-DurazoJVJudas Vargas-Durazo
- Cinthia JhovannaCJCinthia Jhovanna
- Simon Bernard Iloki-AssangaSISimon Bernard Iloki-Assanga
Preprint
- 26 September 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Diabetic retinopathy (DR) is a major microvascular complication of diabetes and a leading cause of vision loss in working-age adults worldwide. The pathophysiology of DR is complex and involves oxidative stress, inflammation, retinal pigment epithelium (RPE) dysfunction, and abnormal angiogenesis. Recent insights into the molecular mechanisms underlying DR have opened new avenues for targeted and personalized therapeutic strategies. In this review, we examine the advances in the understanding of oxidative damage, RPE impairment, and proangiogenic signaling in DR progression. We also highlight emerging treatment modalities, including anti-VEGF agents, gene therapy, and nutraceutical interventions. Future directions emphasize the integration of omics technologies and precision medicine approaches for individualized management. This work provides a critical synthesis of recent findings and identifies promising avenues for research and clinical intervention in DR.Keywords
All Related Versions
This publication has 72 references indexed in Scilit:
- Updates on medical and surgical managements of diabetic retinopathy and maculopathyAsia-Pacific Journal of Ophthalmology, 2025
- Genome-wide association meta-analysis of 88,250 individuals highlights pleiotropic mechanisms of five ocular diseases in UK BiobankEBioMedicine, 2022
- Eye disorders other than diabetic retinopathy in patients with diabetesDiabetes & Metabolism, 2021
- Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysisEuropean Journal of Epidemiology, 2019
- Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of ChinaJAMA, 2017
- Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectivesReviews in Endocrine and Metabolic Disorders, 2008
- Changes in Retinal Neovascularization after Pegaptanib (Macugen) Therapy in Diabetic IndividualsOphthalmology, 2006
- A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular EdemaOphthalmology, 2005
- Intravitreal Triamcinolone Compared With Macular Laser Grid Photocoagulation for the Treatment of Cystoid Macular EdemaAmerican Journal of Ophthalmology, 2005
- Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular EdemaArchives of Ophthalmology (1950), 2003